DXP-106 / Singlomics - LARVOL DELTA

DXP-106, an anti-IL1RAP monoclonal antibody with enhanced ADCC activity, exhibits both in vitro and in vivo anti-tumor effects and has successfully completed IND-enabling studies (AACR 2026) - "DXP-106 is a potent monoclonal antibody that specifically binds to a unique epitope on IL1RAP, broadly inhibits all six IL-1 family signaling pathways, and shows robust anti-tumor activity both in vitro and in vivo. IND-enabling studies have been successfully completed, and the first-in-human (FIH) clinical trial is planned for the first quarter of 2026."

ADC • First-in-human • Preclinical • Oncology • Squamous Cell Carcinoma • IL1B • IL1R1 • IL1RAP • IL33

DXP-106 in Solid Tumor Patients. (clinicaltrials.gov) - P1 | N=54 | Recruiting | Sponsor: Singlomics Biopharmaceuticals Zhuhai Co., Ltd.

Monotherapy • New P1 trial • Breast Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Ductal Adenocarcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • HER-2 • PGR

Singlomics Announces First Patient Dosed in Phase I Clinical Trial of DXP-106 (IL-1RAP mAb) in China (The Manila Times) - "The ongoing first-in-human Phase I study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of DXP-106 in patients with advanced solid tumors."

Trial status • Solid Tumor